Navigation Links
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Date:3/10/2008

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today announced positive interim data from the company's ongoing Phase 2 clinical trial of its lead product candidate, SNS-595, in platinum-resistant ovarian cancer patients.

In this Phase 2 clinical trial, single agent SNS-595 has demonstrated disease control (defined as stable disease, partial response or complete response) in 31 of 35 patients evaluable for best response using GOG-RECIST criteria. Of these 31 patients, one patient had a complete response, four patients had partial responses (two unconfirmed) and 26 patients had a best response of stable disease. All patients enrolled in the trial have previously failed treatment with platinum-containing regimens, and fourteen of the 35 patients have also failed prior treatment with doxorubicin HCl liposome injection (Doxil(R)). Both platinum-resistant and Doxil-resistant patients in the Phase 2 clinical trial have responded to SNS-595 therapy.

"Recurrence rates among ovarian cancer patients remain high, and the majority of refractory patients are resistant to platinum-based therapies. Based on these interim data, SNS-595 appears to be a promising, active agent in a difficult-to-treat ovarian cancer patient population," said William P. McGuire, M.D., Medical Director of the Harry and Jeanette Weinberg Cancer Institute at Franklin Square, and a lead investigator for the Phase 2 trial.

Among forty-five patients with sufficient follow-up to yield safety data, SNS-595 was generally well tolerated at a dose level of 48mg/m2
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
6. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
9. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
10. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  ProteinSimple announced today that it has launched ... assay allows users to detect all proteins separated in ... users can analyze proteins without the need for an ... protein analysis as we know it today. First, the Simple ... no messy gels, no transfer tanks, no blots, no ...
(Date:7/28/2014)... Germany and LONDON ... , Collaboration aims to create and commercialize ... guide the use of IRESSA  for non-small cell lung ... on QIAGEN,s FDA-approved  therascreen   EGFR test and is planned ... automated instruments  Project enabled by AstraZeneca master ...
(Date:7/28/2014)... 28, 2014 OmPrompt today ... to help it meet the global demand for ... and logistics. Albion joins Shackleton Ventures. ... Over the past 18 months OmPrompt has underpinned ... management team and its operations. The new funding ...
Breaking Medicine Technology:ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6OmPrompt Funded for Customer Automation Management Market Expansion 2
(Date:7/28/2014)... 2014 Thousands of DePuy Pinnacle hip ... individuals who were allegedly injured by a metal-on-metal version ... forward in U.S. District Court, Northern District of Texas, ... on July 18, 2014, U.S. District Judge Ed Kinkeade ... Plaintiffs’ Steering Committee that sought the deposition of a ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Ticket Down ... Colombia tickets in Miami, FL at the Sun Life ... South American football between Argentina and Brazil has is one ... stronger worldwide, more rivalries are forming on a consistent basis. ... reached a new height in the recent 2014 World Cup. ...
(Date:7/28/2014)... 2014 (HealthDay News) --,The more chronic medical conditions people ... may be, a new study claims. Since ... issues, scientists at Johns Hopkins Bloomberg School of Public ... why gains in life expectancy are slowing in the ... as diabetes, kidney disease and heart failure is now ...
(Date:7/28/2014)... News) -- Endurance runners are far more likely to ... according to a new study. The researchers ... warm climates are actually 10 times more likely to ... common sudden death of a young and apparently healthy ... irregular heartbeat, often gets a lot more media attention. ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2
... COLUMBUS, Ohio Chronic inhalation of polluted air appears ... white blood cells, setting off events that lead to ... model. This finding narrows the gap in researchers, ... the risk for cardiovascular problems and other diseases. ...
... Jeremy M. Berg, Ph.D., director of the National ... Institutes of Health (NIH), and Norman P. Neureiter, Ph.D., ... the American Association for the Advancement of Science (AAAS), ... Service Award for their vision and leadership in science ...
... way of discovering a gene,s function is to switch it ... an organism. If a gene is essential for survival, however, ... the gene,s function can be determined. Researchers at Cold Spring ... interference (RNAi) technology to temporarily turn off any essential gene ...
... release is available in French . Montreal, ... treat tics in Tourette syndrome may be as effective as ... a new study published in a special edition of the ... Research Centre of the Louis-H. Lafontaine Hospital affiliated with Universit ...
... HealthDay Reporter , WEDNESDAY, April 13 (HealthDay News) ... in controlling and containing the spread of potentially lethal ... one study showed that certain interventions could decrease transmissions ... the other found no improvement when a somewhat different ...
... HealthDay Reporter , WEDNESDAY, April 13 (HealthDay News) -- The ... to a decade before symptoms appear, a new study finds. ... Massachusetts General Hospital in Boston did brain imaging tests on ... the 33 people in the Mass General group, eight developed ...
Cached Medicine News:Health News:Polluted air leads to disease by promoting widespread inflammation 2Health News:Polluted air leads to disease by promoting widespread inflammation 3Health News:Polluted air leads to disease by promoting widespread inflammation 4Health News:Polluted air leads to disease by promoting widespread inflammation 5Health News:American Chemical Society honors Jeremy Berg and Norman Neureiter with Public Service Award 2Health News:American Chemical Society honors Jeremy Berg and Norman Neureiter with Public Service Award 3Health News:CSHL team perfects non-lethal way of switching off essential genes in mice 2Health News:CSHL team perfects non-lethal way of switching off essential genes in mice 3Health News:Tourette Syndrome: non-drug therapy to reduce tics 2Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 2Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 3Health News:Brain May Shrink in Decade Before Alzheimer's Symptoms Appear 2Health News:Brain May Shrink in Decade Before Alzheimer's Symptoms Appear 3Health News:Brain May Shrink in Decade Before Alzheimer's Symptoms Appear 4
IRMA kit for detection of the cardiac marker Myoglobin...
... The assay is an immunometric ... measurement of Prolactin in human ... the sample is bound by ... different epitopes. One antibody is ...
... Immunosorbent Assay (ELISA) serves the quantitative,determination of ... serum and,urine. In a 1 hour incubation ... bound to an,available excess of polyclonal rabbit ... surface of the microtitre plates. After a ...
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
Medicine Products: